Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05407324 · ClinicalTrials.gov registry record · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
- 20
- Study locations
NCT05407324: Recruiting Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Corcept Therapeutics.
NCT05407324 is a Phase 2 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 279 participants, below the 895-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05407324, a Phase 2 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Primary Outcome
This outcome measure is assessed in study Part 1.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dazucorilant 300 mg
- DRUG Dazucorilant 150 mg
- DRUG Dazucorilant
Study Locations (20)
Other
- 108 - Leuven
- 422 - Bron
- 258 - Lille
- 257 - Limoges
- 261 - Marseille
- 423 - Montpellier
- 259 - Nice
- 262 - Paris
- 256 - Tours
- 255 - Berlin
- 270 - Bonn
- 268 - Dresden
- 260 - Hanover
- 265 - Jena
Arizona
- 062 - Phoenix
California
- 278 - San Francisco
New Jersey
- 287 - Neptune City
New York
- 353 - New York
Ontario
- 425 - Hamilton
Quebec
- 273 - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT05407324 shows while recruiting
NCT05407324 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, below the 895-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05407324 names 20 study sites across 7 states, led by Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05407324 about?
NCT05407324 is a clinical study titled "Dazucorilant in Patients With Amyotrophic Lateral Sclerosis". The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
What is the current status of trial NCT05407324?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2022-11-15. Estimated completion is 2027-11.
What conditions does trial NCT05407324 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT05407324?
The interventions under investigation include: Placebo (OTHER), Dazucorilant 300 mg (DRUG), Dazucorilant 150 mg (DRUG), Dazucorilant (DRUG).
Who is sponsoring clinical trial NCT05407324?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05407324 being conducted?
This trial has 20 study locations across Arizona, California, New Jersey, New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05407324's enrollment target sits among peer trials
279 27th of 102 higher than 76 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
- NCT06876662 · 279 participants · Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI